Pediatric acute myeloid leukemia (AML) is one of the most common acute leukemias in children. While treatment outcomes have ...

NPM1-mutated AML prognosis was refined using a new genetic model integrating co-mutations, improving risk classification and ...

Acute myeloid leukemia (AML) can occur in both children and adults. However, the genetic drivers of disease can differ depending on the patient’s age and knowing this information may inform on ...

Researchers working on an incurable blood cancer can now use a new lab model that could make testing potential new treatments and diagnostics easier and quicker, new research has found. Working with ...

Disruptions in transcriptional regulation during hematopoiesis can lead to abnormal hematopoietic differentiation and the development of leukemia. Understanding the underlying mechanisms of disease ...

TP53 mutations are crucial in cancer development and treatment response, influenced by genetic and environmental factors. In CLL and AML, TP53 serves as a significant prognostic marker, affecting ...

A genetic fault has been identified in people with an aggressive type of leukemia that can significantly affect how they respond to treatment. The findings come from a clinical trial led by the ...

Researchers from the University of Toronto (Canada) have presented a new high-resolution gene expression atlas that shows the normal differentiation process of hematopoietic cells at the American ...

University of Cincinnati Cancer Center experts will present abstracts at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition Dec. 7-10 in San Diego. Trial finds AML drug is ...

Compared with white patients, Black patients with acute myeloid leukemia (AML) were on average more than five years younger at diagnosis, more than 30% more likely to die of their disease, and more ...